Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort

Table 5 Median values of target and LOARs dose between original and lymphocyte-sparing thoracic IMRT or proton radiotherapy

Structures		Planning median			Significance
Name	Objectives	Original (n = 10)	lymphocyte-sparing IMRT (n = 10)	lymphocyte-sparing thoracic IMPT (n = 10)	Original vs. lymphocyte-sparing IMRT	Original vs. lymphocyte-sparing thoracic IMPT	lymphocyte-sparing IMRT vs. IMPT
PTV	V95 ≥ 95%	99.7%	99.8%	-	0.62
CTV	V95 ≥ 95%	-	-	99.99%
TVB
Mean TVB dose	19 Gy	24.8 Gy	22.5 Gy	18.7 Gy	0.0014	0.0018	0.012
TVB V5	81%	93.5%	90.8%	77.0%	0.66	0.0002	0.00091
TVB V10	77%	85.4%	78.6%	65.38%	0.005	0.0013	0.0052
TVB V20	70%	67.5%	58.3%	47.2%	0.76	0.004	0.045
Mean CPD	11 Gy	11.9 Gy	12.0 Gy	6.1 Gy	0.015	< 0.0001	< 0.0001
Mean ribs dose	8 Gy	8.05 Gy	7.99 Gy	5.0 Gy	0.034	< 0.0001	< 0.0001
Mean spleen dose	4 Gy	7.43 Gy	3.87 Gy	3.77 Gy	0.0026	0.0018	0.29
Lungs
Mean dose	15 Gy	9.78 Gy	9.83 Gy	5.24 Gy	0.14	< 0.0001	< 0.0001
V5	60%	56.45%	56.5 Gy	24.3%	0.35	< 0.0001	< 0.0001
V20	30%	14.15%	14.45%	9.38%	0.13	0.0019	0.002
V30	20%	3.25%	3.5%	4.14%	0.005	0.38	0.81
Heart
Mean dose	15 Gy	17.56 Gy	18.4 Gy	7.17 Gy	0.013	< 0.0001	< 0.0001
V30	40%	15.6%	17.7%	11.24%	0.04	0.0013	0.0012
Spinal cord	Dmax < 45	37.7 Gy	36.5 Gy	34.3 Gy	0.20	0.013	0.021

Abbreviations: PTV: plan treatment volume; CTV: clinical treatment volume; mCPD: mean cardiopulmonary dose; TVB: thoracic vertebrae body; IMRT: intensity modulated radiation therapy; IMPT: intensity modulated proton therapy;

ISSN: 1748-717X